Diagnosis and management of iliofemoral deep vein thrombosis: Clinical practice guideline

CMAJ

Volumn 187, Issue 17, 2015, Pages 1288-1296

  Liu, David ^a   Peterson, Erica ^a   Dooner, James ^b   Baerlocher, Mark ^c   Zypchen, Leslie ^a   Gagnon, Joel ^a   Delorme, Michael ^d   Sing, Chad Kim ^e   Wong, Jason ^e   Guzman, Randolph ^f   Greenfield, Gavin ^g   Moodley, Otto ^h   Yenson, Paul ^a  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b VICTORIA GENERAL HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d KELOWNA GENERAL HOSPITAL   (Canada)

^e FOOTHILLS HOSPITAL   (Canada)

^f ST BONIFACE GENERAL HOSPITAL   (Canada)

^g UNIVERSITY OF CALGARY   (Canada)

^h ROYAL UNIVERSITY HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; APIXABAN; DABIGATRAN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; RUTOSIDE DERIVATIVE; WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULATION; BLEEDING; BLOOD CLOT LYSIS; COMPRESSION STOCKING; DEEP VEIN THROMBOSIS; DEVICE SAFETY; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; DRUG CONTRAINDICATION; FEMORAL VEIN; HUMAN; ILIAC VEIN; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PHLEBOGRAPHY; POSTTHROMBOSIS SYNDROME; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBECTOMY; TREATMENT INDICATION; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM; ALGORITHM; DIAGNOSTIC IMAGING; ECHOGRAPHY; FIBRINOLYTIC THERAPY; ILIAC BONE; POSTTHROMBOTIC SYNDROME; TREATMENT OUTCOME; VASCULARIZATION; VENOUS THROMBOSIS;

ALGORITHMS; ANTICOAGULANTS; FEMORAL VEIN; HUMANS; ILIUM; POSTTHROMBOTIC SYNDROME; PRACTICE GUIDELINES AS TOPIC; THROMBOLYTIC THERAPY; TREATMENT OUTCOME; ULTRASONOGRAPHY; VENA CAVA FILTERS; VENOUS THROMBOSIS;

EID: 84947933173     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.141614     Document Type: Article

References (64)

1. White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107(23 Suppl 1):14-8.
2. Vedantham S, Thorpe PE, Cardella J.F., et al.; CIRSE and SIR Standards of Practice Committees. Quality improvement guidelines for the treatment of lower extremity deep vein thrombosis with use of endovascular thrombus removal. J Vasc Interv Radiol 2009; 20(7 Suppl):S227-39.
3. Kahn SR, Shrier I, Julian J.A., et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med 2008; 149:698-707.
4. Douketis JD, Crowther MA, Foster G.A., et al. Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis? Am J Med 2001; 110:515-9.
5. Kahn SR. How I treat postthrombotic syndrome. Blood 2009; 114:4624-31.
6. Watson LI, Armon MP Thrombolysis for acute deep vein thrombosis. Cochrane Database Syst Rev 2004; (4):CD002783.
7. Goldhaber SZ, Buring JE, Lipnick R.J., et al. Pooled analyses of randomized trials of streptokinase and heparin in phlebographically documented acute deep venous thrombosis. Am J Med 1984; 76:393-7.
8. Enden T, Haig Y, Kløw NE, et al.; CaVenT Study Group. Longterm outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet 2012; 379:31-8.
9. Plate G, Akesson H, Einarsson E., et al. Long-term results of venous thrombectomy combined with a temporary arterio-venous fistula. Eur J Vasc Surg 1990; 4:483-9.
10. Plate G, Einarsson E, Ohlin P., et al. Thrombectomy with temporary arteriovenous fistula: the treatment of choice in acute iliofemoral venous thrombosis. J Vasc Surg 1984; 1:867-76.
11. Plate G, Eklof B, Norgren L., et al. Venous thrombectomy for iliofemoral vein thrombosis - 10-year results of a prospective randomised study. Eur J Vasc Endovasc Surg 1997; 14:367-74.
12. Guyatt GH, Oxman AD, Vist G.E., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924-6.
13. Guyatt GH, Oxman AD, Kunz R, et al What is "quality of evidence" and why is it important to clinicians? BMJ 2008; 336:995-8.
14. Guyatt GH, Oxman AD, Kunz R, et al Incorporating considerations of resources use into grading recommendations. BMJ 2008; 336:1170-3.
15. Guyatt GH, Oxman AD, Kunz R, et al Going from evidence to recommendations. BMJ 2008; 336:1049-51.
16. Jaeschke R, Guyatt GH, Dellinger P, et al Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ 2008; 337:a744.
17. Jacobs AK, Kushner FG, Ettinger S.M., et al. ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61:213-65.
18. Jaff MR, McMurtry MS, Archer S.L., et al.; Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011; 123:1788-830.
19. Brozek JL, Akl EA, Alonso-Coello P, et al.; GRADE Working Group. Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy 2009; 64:669-77.
20. Brozek JL, Akl EA, Compalati E, et al; GRADE Working Group. Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations. Allergy 2011; 66:588-95.
21. Brouwers MC, Kho ME, Browman G.P., et al.; AGREE Next Steps Consortium. Development of the AGREE II, part 2: assessment of validity of items and tools to support application. CMAJ 2010; 182:E472-8.
22. Brouwers MC, Kho ME, Browman G.P., et al.; AGREE Next Steps Consortium. Development of the AGREE II, part 1: performance, usefulness and areas for improvement. CMAJ 2010; 182:1045-52.
23. Fink A, Kosecoff J, Chassin M., et al. Consensus methods: characteristics and guidelines for use. Am J Public Health 1984; 74:979-83.
24. Hirsh J, Lee AY How we diagnose and treat deep vein thrombosis. Blood 2002; 99:3102-10.
25. Bates SM, Jaeschke R, Stevens S.M., et al. Diagnosis of DVT: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141(2 Suppl):e351S-418S.
26. Chinsakchai K, Ten Duis K, Moll FL, et al Trends in management of phlegmasia cerulea dolens. Vasc Endovascular Surg 2011; 45:5-14.
27. Kearon C, Ginsberg JS, Hirsh J. The role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism. Ann Intern Med 1998; 129:1044-9.
28. Erkens PM, Prins MH Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2010; (9):CD001100.
29. Büller H.R., Davidson BL, Decousus H, et al Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140:867-73.
30. Martel N, Lee J, Wells PS Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005; 106:2710-5.
31. Bauersachs R, Berkowitz SD, Brenner B, et al Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363:2499-510.
32. Büller H.R., Prins MH, Lensin A.W., et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366:1287-97.
33. Prins MH, Lensing AW, Bauersachs R, et al; EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013; 11:21.
34. Schulman S, Kearon C, Kakkar A.K., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361:2342-52.
35. Agnelli G, Buller HR, Cohen A, et al Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799-808.
36. Kearon C, Akl EA, Comerota A.J., et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141(2 Suppl):e419S-94S.
37. Agnelli G, Buller HR, Cohen A, et al Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368: 699-708.
38. Schulman S, Kearon C, Kakkar A.K., et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368:709-18.
39. Cancer-associated venous thromboembolic disease. Version 1.2015. Fort Washington (PA): National Comprehensive Cancer Network; 2015. Available: www.nccn.org/professionals/physician-gls/pdf/vte.pdf (accessed 2015 Sept. 15). Login required to access content.
40. Lyman GH, Khorana AA, Kuderer N.M., et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31:2189-204.
41. Akl EA, Kahale L, Barba M., et al. Anticoagulation for the longterm treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2014; 7:CD006650.
42. Decousus H, Leizorovicz A, Parent F., et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998; 338:409-15.
43. PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 2005; 112:416-22.
44. Mismetti P, Ennezat PV, Quéré I, et al. Prevention of pulmonary embolism recurrences by retrievable vena cava filter: results of the randomized multicenter trial PREPIC 2 [abstract]. J Thromb Haemost 2013; 11(Suppl s2):28.
45. Mission JF, Kerlan RK Jr, Tan JH, et al. Rates and predictors of plans for inferior vena cava filter retrieval in hospitalized patients. J Gen Intern Med 2010; 25:321-5.
46. McKenzie S, Gibbs H, Leggett D., et al. An Australian experience of retrievable inferior vena cava filters in patients with increased risk of thromboembolic disease. Int Angiol 2010; 29:53-7.
47. Seshadri T, Tran H, Lau K.K., et al. Ins and outs of inferior vena cava filters in patients with venous thromboembolism: the experience at Monash Medical Centre and review of the published reports. Intern Med J 2008; 38:38-43.
48. Tiwari A, Saw C, Li M., et al. Use of inferior vena cava filters in a tertiary referral centre in Australia. ANZ J Surg 2010; 80:364-7.
49. Dabbagh O, Nagam N, Chitima-Matsiga R, et al. Retrievable inferior vena cava filters are not getting retrieved: Where is the gap? Thromb Res 2010; 126:493-7.
50. Hammond CJ, Bakshi DR, Currie R.J., et al. Audit of the use of IVC filters in the UK: experience from three centres over 12 years. Clin Radiol 2009; 64:502-10.
51. Removing retrievable inferior vena cava filters: FDA safety communication. Silver Spring (MD): US Food and Drug Administration; 2014. Available: www.fda.gov/medicaldevices/safety/alertsandnotices/ucm396377.htm (accessed 2015 Sept. 18).
52. Turpie AG, Levine MN, Hirsh J, et al Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis. Results of a randomized trial. Chest 1990; 97(4 Suppl):172S-175S.
53. Meissner MH, Gloviczki P, Comerota A.J., et al. Early thrombus removal strategies for acute deep venous thrombosis: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg 2012; 55:1449-62.
54. Casey ET, Murad MH, Zumaeta-Garcia M, et al. Treatment of acute iliofemoral deep vein thrombosis. J Vasc Surg 2012; 55:1463-73.
55. Comerota AJ. Thrombolysis for deep venous thrombosis. J Vasc Surg 2012; 55:607-11.
56. Kahn SR, Hirsch A, Shrier I. Effect of postthrombotic syndrome on health-related quality of life after deep venous thrombosis. Arch Intern Med 2002; 162:1144-8.
57. Baldwin MJ, Moore HM, Rudarakanchana N, et al Post-thrombotic syndrome: a clinical review. J Thromb Haemost 2013; 11:795-805.
58. Kahn SR, Partsch H, Vedantham S., et al.; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of post-thrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization. J Thromb Haemost 2009; 7:879-83.
59. Brandjes DP, Buller HR, Heijboer H, et al Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997; 349:759-62.
60. Aschwanden M, Jeanneret C, Koller M.T., et al. Effect of prolonged treatment with compression stockings to prevent postthrombotic sequelae: a randomized controlled trial. J Vasc Surg 2008; 47:1015-21.
61. Ginsberg JS, Hirsh J, Julian J., et al. Prevention and treatment of postphlebitic syndrome: results of a 3-part study. Arch Intern Med 2001; 161:2105-9.
62. Prandoni P, Lensing AW, Prins M.H., et al. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med 2004; 141:249-56.
63. Kahn SR, Shapiro S, Wells P.S., et al. Compression stockings to prevent post-thrombotic syndrome: a randomised placebocontrolled trial. Lancet 2014; 383:880-8.
64. Frisius J, Ebeling M, Karst M., et al. Prevention of venous thromboembolic complications with and without intermittent pneumatic compression in neurosurgical cranial procedures using intraoperative magnetic resonance imaging. A retrospective analysis. Clin Neurol Neurosurg 2015; 133:46-54.